{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:49:05Z","timestamp":1768438145400,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.cbi.2020.109288","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T20:56:12Z","timestamp":1602881772000},"page":"109288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis"],"prefix":"10.1016","volume":"332","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-2996","authenticated-orcid":false,"given":"Mustafa","family":"Ergul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2809-8946","authenticated-orcid":false,"given":"Filiz","family":"Bakar-Ates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2020.109288_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.cbi.2020.109288_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.cbi.2020.109288_bib4","doi-asserted-by":"crossref","first-page":"E3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2020.109288_bib5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 inhibitors in cancer therapy: from laboratory to clinics","volume":"15","author":"Gutteridge","year":"2016","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.cbi.2020.109288_bib6","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1038\/onc.2017.113","article-title":"Playing polo during mitosis: PLK1 takes the lead","volume":"36","author":"Combes","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2020.109288_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.cbi.2020.109288_bib8","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.2174\/1871520619666190618162828","article-title":"RO3280: a novel PLK1 inhibitor, suppressed the proliferation of MCF-7 breast cancer cells through the induction of cell cycle arrest at G2\/M point","volume":"19","author":"Ergul","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.cbi.2020.109288_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jclinpath-2016-203656","article-title":"Molecular interactions of polo-like kinase 1 in human cancers","volume":"69","author":"Weng Ng","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.cbi.2020.109288_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/genes10030208","article-title":"The mitotic cancer target polo-like kinase 1: oncogene or tumor suppressor?","volume":"10","author":"de C\u00e1rcer","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.cbi.2020.109288_bib11","first-page":"190","article-title":"PLK-1: angel or devil for cell cycle progression","volume":"1865","author":"Kumar","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2020.109288_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tranon.2015.03.010","article-title":"Targeting polo-like kinases: a promising therapeutic approach for cancer treatment","volume":"8","author":"Liu","year":"2015","journal-title":"Transl Oncol"},{"key":"10.1016\/j.cbi.2020.109288_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/705745","article-title":"PLK-1 targeted inhibitors and their potential against tumorigenesis","volume":"2015","author":"Kumar","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.cbi.2020.109288_bib14","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-10-0095","article-title":"Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability","volume":"9","author":"Degenhardt","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.cbi.2020.109288_bib15","doi-asserted-by":"crossref","first-page":"16115","DOI":"10.1038\/s41598-017-16394-2","article-title":"The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation","volume":"7","author":"Smith","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2020.109288_bib16","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/mp500492r","article-title":"Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1","volume":"11","author":"Wu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.cbi.2020.109288_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cm.21504","article-title":"Regulating a key mitotic regulator, polo-like kinase 1 (PLK1)","volume":"75","author":"Colicino","year":"2018","journal-title":"Cytoskeleton (Hoboken)"},{"key":"10.1016\/j.cbi.2020.109288_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.cbi.2020.109288_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/bioengineering5040083","article-title":"GSK461364A, a polo-like kinase-1 inhibitor encapsulated in polymeric nanoparticles for the treatment of glioblastoma multiforme (GBM)","volume":"5","author":"Velpurisiva","year":"2018","journal-title":"Bioengineering"},{"key":"10.1016\/j.cbi.2020.109288_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/15384101.2016.1148838","article-title":"Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer","volume":"15","author":"Li","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cbi.2020.109288_bib21","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1158\/0008-5472.CAN-09-0945","article-title":"Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis","volume":"69","author":"Gilmartin","year":"2009","journal-title":"Canc. Res."},{"issue":"11","key":"10.1016\/j.cbi.2020.109288_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224420","article-title":"Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer","volume":"14","author":"Giordano","year":"2019","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.cbi.2020.109288_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/jcmm.13018","article-title":"Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells","volume":"21","author":"Zhang","year":"2017","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.cbi.2020.109288_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.neo.7900101","article-title":"Cell cycle and apoptosis","volume":"2","author":"Pucci","year":"2000","journal-title":"Neoplasia"},{"key":"10.1016\/j.cbi.2020.109288_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2020.109288_bib26","first-page":"51","article-title":"Analyzing the G2\/M checkpoint","volume":"280","author":"Stark","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cbi.2020.109288_bib27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1089\/thy.2013.0037","article-title":"The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations","volume":"23","author":"Russo","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.cbi.2020.109288_bib28","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.ejca.2013.05.013","article-title":"Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation","volume":"49","author":"Tandle","year":"2013","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.cbi.2020.109288_bib29","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.18632\/oncotarget.14268","article-title":"The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models","volume":"8","author":"Pajtler","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2020.109288_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12906-017-1583-9","article-title":"Sinularin induces DNA damage, G2\/M phase Arrest, and apoptosis in human hepatocellular carcinoma cells","volume":"17","author":"Chung","year":"2017","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.cbi.2020.109288_bib31","doi-asserted-by":"crossref","first-page":"49151","DOI":"10.1039\/C7RA10346H","article-title":"S-Allylmercaptocysteine induces G2\/M phase arrest and apoptosis via ROS-mediated p38 and JNK signaling pathway in human colon cancer cells in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.cbi.2020.109288_bib32","first-page":"1559","article-title":"Modulation of G2\/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.cbi.2020.109288_bib33","first-page":"967","article-title":"Ganetespib induces G2\/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling","volume":"51","author":"Lee","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cbi.2020.109288_bib34","doi-asserted-by":"crossref","first-page":"e2247","DOI":"10.1038\/cddis.2016.138","article-title":"Erianin induces G2\/M-phase arrest, apoptosis, and autophagy via the ROS\/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo","volume":"7","author":"Wang","year":"2016","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.cbi.2020.109288_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.cbi.2020.109288_bib36","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.3390\/ijms20174133","article-title":"A cell's fate: an overview of the molecular biology and genetics of apoptosis","volume":"24;20","author":"Cavalcante","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"586","key":"10.1016\/j.cbi.2020.109288_bib37","article-title":"Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage","volume":"30","author":"Bakar-Ates","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.cbi.2020.109288_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways targeted cancer therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharmaceut. Bull."},{"issue":"8","key":"10.1016\/j.cbi.2020.109288_bib39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10585-011-9421-9","article-title":"Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain","volume":"28","author":"Qian","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.cbi.2020.109288_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biopha.2015.07.005","article-title":"BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells","volume":"74","author":"Prashanth Kumar","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2020.109288_bib41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/biom9110735","article-title":"Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements","volume":"9","author":"Aggarwal","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.cbi.2020.109288_bib42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.clinbiochem.2005.08.008","article-title":"A new automated colorimetric method for measuring total oxidant status","volume":"38","author":"Erel","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cbi.2020.109288_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clinbiochem.2003.11.015","article-title":"A novel automated direct measurement method for total antioxidant capacity using a new gener- ation, more stable ABTS radical cation","volume":"37","author":"Erel","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cbi.2020.109288_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.canlet.2014.12.023","article-title":"Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells","volume":"357","author":"Choi","year":"2015","journal-title":"Canc. Lett."},{"key":"10.1016\/j.cbi.2020.109288_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10238-011-0166-1","article-title":"Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells","volume":"13","author":"Pezuk","year":"2013","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cbi.2020.109288_bib46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ebiom.2019.02.012","article-title":"A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma","volume":"41","author":"Wu","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cbi.2020.109288_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.08.007","article-title":"Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer","volume":"436","author":"Wang","year":"2018","journal-title":"Canc. Lett."},{"issue":"3","key":"10.1016\/j.cbi.2020.109288_bib48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1535-7163.MCT-11-0762","article-title":"TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens","volume":"11","author":"Hikichi","year":"2012","journal-title":"Mol. Canc. Therapeut."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279720314885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279720314885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:00:43Z","timestamp":1757858443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279720314885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":47,"alternative-id":["S0009279720314885"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2020.109288","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2020.109288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109288"}}